News Luglio 2017

GAMA Healthcare Disinfectant Compatibility Statement

July 2017

The Therapeutic Goods Administration (TGA) recently published a Medical Devices Safety Update (vol. 5, no. 3, May 2017) which contained an article entitled ‘Disinfectants and detergents can damage medical equipment plastics’. GAMA Healthcare are aware that this has caused a lot of concern and confusion in the Australian marketplace.

We welcome the publication of the following clarifications to the alert which is now available to view on the TGA website:

i. Certain disinfectant wipes and detergents can damage medical devices if the cleaning agent is incompatible with the device’s plastic surfaces*.
*The TGA considers cleaning agents that contain levels of benzalkonium chloride below 5-10% are safe to use on medical devices. Disinfectants generally use about 0.5% benzalkonium chloride, which is considered noncorrosive at these levels.

ii. Detergent wipes used by the hospital to clean the pumps contained the ingredient ‘benzalkonium chloride’. This is classed as a quaternary ammonium compound which is a corrosive ingredient and therefore should not be used**.
** Benzalkonium chloride is unsafe at a concentration above 10% and therefore should not be used without being diluted.

iii. When cleaning medical devices the TGA recommends that health facilities:
• Review all decontamination processes that use a disinfectant wipe or detergent containing quaternary ammonium compounds on a plastic surface***.
*** Particularly if the surface is made of polycarbonate material.

GAMA Healthcare Ltd. would like to confirm to all our customers that Clinell Universal Wipes contain benzalkonium chloride at a concentration of less than 0.5% and therefore per the TGA clarification are considered non-corrosive at this level.

We have also been advised that the wording of the alert specifically referencing detergent wipes has been interpreted to mean neutral detergent wipes. GAMA Healthcare would like to confirm Clinell Detergent wipes do not contain benzalkonium chloride.

We fully support the TGA statement that equipment manufacturers’ cleaning recommendations should be followed.

GAMA Healthcare continues to work with equipment manufacturers on material compatibility and welcomes the opportunity to collaborate on any items which require disinfection and are not currently listed on our approved equipment list.

For guidance of on using disinfectant wipes, please download the Instructions For Use below.

Signed, on behalf of GAMA Healthcare Ltd.,
Dr. Guy Braverman
Managing Director & Co-Founder

News Giugno 2017

GAMA Healthcare makes The Sunday Times HSBC International Track 200

June 2017


The Sunday Times HSBC International Track 200 ranks Britain’s mid-market private companies with the fastest-growing international sales, measured over their latest two years of available accounts.

This is the 8th year of The Sunday Times HSBC International Track 200, the league table of Britain’s mid-market private companies with the fastest-growing international sales. The International Track 200 ranks the 200 mid-market companies (25m+ total sales) based on their growth in international sales over the last two years of available data; whereas our SME Export Track 100 ranks companies with sales of less than 25m. Despite the backdrop of volatile international markets and the prospect of the UK leaving the EU, this year’s league table findings indicate the breadth of UK companies still making remarkable headway overseas.

GAMA Healthcare is delighted to make its debut entry this year at number 98 with a 41.91% increase in international sales over the last 2 years.

News Maggio 2017

PRESS RELEASE – GAMA Healthcare Ltd acquire Australian distributor, AMCLA Pty Ltd

May 2017

[17th May 2017, WATFORD, UK] Leading infection control specialists, GAMA Healthcare Ltd, acquires the Clinell division of their Australian distributor, AMCLA Pty Ltd., in Victoria. This significant investment demonstrates GAMA’s continued commitment to infection prevention – providing outstanding education, training and clinical support to healthcare professionals across the world.

Plans for growth, support and education
GAMA will take over the current office in Mornington, Victoria and will retain all AMCLA personnel. The business unveils ambitious investment plans to emulate success in the UK – aiming to double the current workforce over the next twelve months. With headquarters in Watford, England, GAMA now has offices in six cities, across three continents.

“This is a very exciting time for us, as we enhance our service in Australia”, says Dr Guy Braverman, Managing Director and Co-Founder of GAMA. “As world leaders in infection prevention we are committed to empowering healthcare professionals to make the right choices to achieve the best clinical outcomes. Through our growing team of experienced clinical nurse trainers and area managers, we can increase support and after-sales service to meet the individual needs of
every hospital.”

In the UK, GAMA provides bespoke, local training through group sessions, ward-based training and practitioner meetings – delivered by a team of infection control specialists. “Our organisational support training programme is valued very highly by our UK customers and we look forward to implementing this in Australia,” says Dr Martin Kiernan, Clinical Director at GAMA. “We have developed the most advanced and fully customisable tablet-based training suite that is free to all customers. In the last six months of 2016, we hosted over 250 training days. This support has been critical in developing new business opportunities and retaining key contracts.

Commitment to products, people and partnerships
Founded in 2004 by two medical doctors, GAMA Healthcare has become a world leading developer and manufacturer of infection prevention technology. The Clinell range is the NHS’s number 1 brand, providing a range of product lines for surface care, hygiene monitoring, and patient skincare. GAMA’s dedication to infection prevention is demonstrated through both product innovation and continued investment in people and partnerships.

Media enquiries
For all media enquiries and interview requests please contact Beth Lowes at ROAD Communications on: Questo indirizzo email è protetto dagli spambots. E' necessario abilitare JavaScript per vederlo. '; document.write(''); document.write(addy_text1507); document.write('<\/a>'); //-->\n Questo indirizzo email è protetto dagli spambots. E' necessario abilitare JavaScript per vederlo. or call +44(0)208 995 5832.

About GAMA Healthcare
Formed in 2004 by two medical doctors, GAMA Healthcare is a world leading developer and manufacturer of infection prevention products for the healthcare sector. Their focus remains on quality, innovation and continual improvement. We work closely with our customers, identifying their needs and providing solutions to real problems. Our new and continually evolving product lines – specialising in surface care, hygiene monitoring, patient skin care and easyclean computer accessories – offer market leading solutions to infection control problems found throughout healthcare provision.

GAMA Healthcare products are marketed under the brands Clinell, Carell and Cleanall and are widely used in many hospitals in around the worldwide. In the last 13 years, they have become the largest supplier of wet and dry wipes in the United Kingdom, with at least one of their products used in every National Health Service hospital. They distribute to over 60 countries around the world and the list continues to grow.

Since 2007, AMCLA – a family owned specialist import and distribution company, have brought world class healthcare delivery solutions through their two key sales divisions: medical and pharmaceutical. AMCLA have built a reputation for supplying innovative, high quality products to healthcare markets.


New blog post!

December 2016


Single room, anyone?

There has been lots of debate over many years about the extent to which hospitals should provide single rooms for patients. Read more…

Clinell UV360 Significantly Reduces Clostridium difficile Incidence

October 2016

NEW YORK (October 6, 2016) – Ultraviolet C light disinfection to clean unoccupied patient rooms significantly reduced C. difficile infections (CDI) in high-risk patients who later occupied those rooms, according to a study published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America. The no-touch device, used after patients with CDI were discharged from the hospital, also resulted in substantial healthcare savings, estimated between $350,000 and $1.5 million annually. 

“UV light disinfection is a fast, safe, and effective technology to reduce the risk of C. difficile infection associated with the hospital environment,” said David Pegues, MD, lead author of the study and a professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania.
“The success of this technology is dependent on Environmental Services employees as a critical partner in our ongoing efforts to eliminate hospital-acquired infections such as C. difficile and
to improve patient safety.”

The study was conducted in three hematology-oncology units at the Hospital of the University of Pennsylvania during a one-year period (February 2014-January 2015). Results showed that adding UV disinfection to typical disinfection protocols reduced the incidence of CDI by 25 percent among new patients in these units, compared to the prior year. At the same time, CDI rates increased 16 percent in the non-study units during this period. The team found that using the ultraviolet robot after a room cleaning by members of the Environmental Services team not only reduced the number of infections, but did so without adversely impacting room turnaround time. According to this study, room cleaning took only five minutes longer on average compared to non-study units.

“These findings have real implications for both health systems and patients. The effectiveness and efficiency of UV-C robots make it a practical and cost effective technology that will benefit hospitals around the country and save people’s lives,” said Pegues.

The technique, known as ultraviolet wavelength C germicidal irradiation, uses short-wavelength ultraviolet light to kill microorganisms. CDI is one of the most common healthcare-acquired infections in the United States and is associated with serious complications. It is resistant to many surface disinfectants and can persist on surfaces, making it an ongoing risk for transmission to patients.

While the UV disinfection device proved to be effective at reducing CDI incidence, it showed no effect on other healthcare-associated infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

David Pegues, Jennifer Han, Cheryl Gilmar, Brooke McDonnell, Steven Gaynes. “Impact of Ultraviolet Germicidal Irradiation for Terminal Room Disinfection on C. difficile Infection Incidence among Hematology Oncology Patients.” Web (October 6, 2016).

IPS 2016 Quiz Me winners

October 2016

This year we had a great turn out for the Quiz Me game, thanks for coming along! The winners from each day were Karen Hawker, Kirsty Louise Morgan and Jean Robinson. Congratulations, enjoy your tablet and Amazon vouchers!img_4155

IPS 2016 #clinellcandy Twitter wall winners

October 2016

This years Twitter winners for the #clinellcandy stand were Carley Baker, Kerry Ord and Gary! They each had the best photo throughout the show! Congratulations, enjoy the chocolate hamper prize!img_4101

Sporicidal Granules for high level disinfection

October 2016


New evidence shows that flooring can be a reservoir for pathogens of significance in healthcare.

Uses Peracetic Acid (PAA) Technology
PAA generating products are now considered a suitable substitute in situations where 1,000 and 10,000 ppm of chlorine are recommended.
Unique granule formulation
Easily mixed within bespoke 1L and 2.5L jugs allowing quick and easy activation, avoiding dilution errors common with chlorine tablets.
ColourActive Technology
Once active the solution turns red in colour. After 24 hours it becomes colourless, indicating it is no longer active, allowing you to always know you are using an effective solution.
More effective than chlorine
PAA has been shown to be more effective than chlorine against C. difficile5,6 and unlike chlorine, PAA is not deactivated by organic matter.
Safer than Chlorine
Peracetic acid breaks down into the harmless, environmentally friendly by-products of water, carbon dioxide and oxygen.


Cost-effectiveness of C. difficile prevention

How much does it cost to prevent the transmission of C. difficile? And is switching to an automated room decontamination (ARD) system for the prevention to reduce environmental contamination with C. difficile spores cost effective? Whilst no formal cost-effectiveness evaluations have been published, there is enough evidence to suggest that switching to an automated room decontamination system will be cost-effective given the published scale of reduction in C. difficile transmission, and the per-case cost of C. difficle infection.
C. difficile infection can be an extremely expensive outcome for a patient. Leaving aside the important socioeconomic impact for the individual and obvious human cost, a recent review suggests that each case costs somewhere between £2000 and 19,500. A number of studies have shown that automated room decon systems reduce the incidence of CDI (see the summary table below). Whilst these studies are really non-comparable – performed in different settings, with a different baseline rate of CDI, and a different set of background interventions, a crude mean percentage reduction was 44%. (Incidentally, this suggests that 44% of CDI is related, directly or indirectly, to contaminated environmental surfaces, which is interesting in itself.)
jon-table-18-11-16 (Click on the table to enlarge)
So, let’s take a hospital with 50 cases of CDI each year. If an ARD system is introduced for the terminal disinfection of rooms following the stay of a patient with CDI, you would expect a 44% reduction in the number of cases, and only 28 cases of CDI – hence 22 cases averted. This would result in a cost saving in the range of £44,000 - £429,000. Taking a mid-point of this range (£240,000) leaves a pretty large envelope in which to fit an ARD service to ensure that all rooms occupied by patients with CDI are decontaminated. Furthermore, it is likely that a service could cover discharges with other pathogens and make an impact on them to – delivering further financial savings.

One final thought: does an infection prevention initiative have to be cost-saving? Or is it acceptable for a prevention initiative to cost more than the associated financial savings? I guess this will depend on the circumstances and the costs involved on both sides of the equation, but it won’t always make sense to accept only cost saving prevention initiatives.


Does chlorhexidine resistance emerge in Staph aureus?


It is prudent to be concerned that regular use of chlorhexidine will ultimately result in reduced chlorhexidine susceptibility and perhaps even resistance. However, a recent long term study performed over a decade in the north of England suggests that regular use of chlorhexidine as part of an MRSA decolonisation regieme does not result in widespread reduced susceptibility.

The regional study in the Yorkshire and Humber region collected a 'snapshot' of S. aureus isolates from 14 laboratories over two days. The isolates were tested for their in vitro susceptibility to chlorhexidine, and the carriage of the qacA gene, which has been associated with reduced chlorhexidine susceptibility. Overall, 1.7% of the 520 isolates carried the qacA gene, and 3.5% had a chlorhexidine minimum inhibitory concentration (MIC) of >2. Whilst there is no clinically defined breakpoint for chlorhexidine resistance, an MIC of >2 is generally considered to be reduced susceptibility. Similar findings were reported for mupiricin, with low levels of in vitro mupirocin resistance detected.

So, despite the widespread use of chlorhexidine for decolonisation of S. aureus carriage in the region, reduced susceptibility was not widespread. Does this mean that reduced susceptibility to chlorhexidine isn't a problem? No, we know from other studies that it can be. It's just that it seems to be a rather rare event, at least in the north of England!


October 2017 Clinell Training Package: Best Educational App! In August 2017, the Clinell Training Package won ‘Best...
This year  IPS annual conference and exhibition was based in our backyard at the ExCeL in London. The usual balance of informative talks, superb...
Flimato prentazione linea Clinell:
Search   Product...

Utilizziamo i cookies per migliorare la tua esperienza sul sito.Chiudendo questo banner, scorrendo questa pagina, cliccando su un link o proseguendo la navigazione in altra maniera, acconsenti all’uso dei cookie. Per avere ulteriori informazioni consulta la nostra Cookie Policy.

Accetto i cookies